Where can I confirm pricing?

Always confirm final pricing directly with the provider. Prices change frequently. GLP1 One Rx verifies provider pricing monthly but the provider's own pricing page is the authoritative source.

Is this medical advice?

No. GLP1 One Rx provides educational information only. Always consult a licensed clinician before starting, changing, or stopping any medication.

Semaglutide and Cardiovascular Health

Overview

Semaglutide is the first GLP-1 with an FDA-approved CV indication for non-diabetic patients. SELECT trial: 20% MACE reduction in non-diabetic adults with overweight/obesity + CVD.

Related guides

Questions readers ask

What did the SELECT trial show for semaglutide?

SELECT, published in NEJM in 2023, found a 20% reduction in major adverse cardiovascular events in adults without diabetes who had overweight or obesity and established cardiovascular disease, over a median follow-up of 39.8 months.

Who does semaglutide’s cardiovascular indication cover?

Semaglutide is the first GLP-1 with an FDA-approved cardiovascular indication for patients without diabetes. It covers adults with overweight or obesity plus established cardiovascular disease, the population studied in the SELECT trial.

Does compounded semaglutide carry the same cardiovascular approval?

No. The cardiovascular indication belongs to the FDA-approved brand product. Compounded drugs are not FDA-approved, so a compounded preparation does not carry that label, and a licensed clinician should decide which option suits a patient with heart disease.

Can Medicare members get Wegovy at a reduced copay?

From July 1, 2026 to December 31, 2027, the Medicare GLP-1 Bridge offers a $50 copay to eligible Part D members for Wegovy, Foundayo or Zepbound KwikPen, with prior authorization and BMI-based criteria. Open enrollment runs October 15 to December 7, 2026.